Prognostic implications of FGFR1 and MYC status in esophageal squamous cell carcinoma

作     者：Dohee Kwon Ji Yun Yun Bhumsuk Keam Young Tae Kim Yoon Kyung Jeon 

作者机构：Department of Pathology Seoul National University Hospital Seoul National University College of Medicine Department of Internal Medicine Seoul National University Hospital Seoul National University College of Medicine Department of Thoracic Surgery Seoul National University Hospital Cancer Research Institute Genomic Medicine Institute Seoul National University College of Medicine Seoul National University College of Medicine 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2016年第22卷第44期

页      面：9803-9812页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Supported by the National Research Foundation for the Global Core Research Center,No.2016005276 the Korea Health Technology R&D Project through the Korea Health Industry Development Institute,No.HI14C0069 

主　　题：Receptor tyrosine kinase Fibroblast growth factor receptor 1 MYC Esophageal squamous cell carcinoma Gene amplification Prognosis Fluorescent in situ hybridization 

摘      要：AIM To investigate the clinicopathological features and prognostic implications of combined MYC and fibroblast growth factor receptor 1(FGFR1) status in esophageal squamous cell carcinomas(ESCCs). METHODS All patients with ESCC(n = 180) underwent surgical resection at Seoul National University Hospital sometime between 2000 and 2013. A tissue microarray was constructed using cores obtained from representative tumor areas of formalin-fixed, paraffin-embedded tissue blocks. FGFR1 and MYC copy numbers were quantified using fluorescence in situ hybridization. The level of MYC expression was determined using immunohistochemistry. FGFR1 and MYC amplification status was compared between primary and metastatic lymph nodes. Univariate and multivariate survival analyses were performed according to adjuvant therapy *** FGFR1 and MYC amplifications were observed in 21.4%(37/173) and 54.2%(91/168) of patients, respectively, while MYC expression was observed in 58.9%(106/180) of patients. There was a positive correlation between MYC amplification and overexpression(P = 0.002). Although FGFR1 amplification was not associated with MYC amplification or expression, 12.3%(20/163) of patients exhibited both FGFR1 amplification and MYC expression. There was also a correlation in FGFR1 amplification status between matched primary tumors and metastatic lymph nodes(P 0.001). MYC expression was higher in ESCCs with p T1(P 0.001) and in those with no lymph node metastasis(P = 0.023). MYC expression was associated with prolonged diseasefree survival(P = 0.036) and overall survival(OS)(P = 0.017) but was not an independent prognostic factor. FGFR1 amplification was an independent predictor for prolonged OS in all patients(P = 0.029) and in those who did not receive adjuvant therapy(P = 0.013). Combined FGFR1 amplification and MYC expression predicted better OS in patients who did not receive adjuvant therapy(P = 0.034) but not in those who did receive adjuvant ***